Navigation Links
AtheroNova to Present at the 2013 Aegis Healthcare Conference in Las Vegas
Date:9/19/2013

ts are based upon the current beliefs and expectations of AtheroNova's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; AtheroNova's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of AtheroNova's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

AtheroNova undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in AtheroNova's 2012 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).


'/>"/>
SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Announces a New Board Member
4. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
5. AtheroNova Releases 2011 Financial Results
6. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
7. AtheroNova Names New Director
8. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
9. AtheroNova Adds New Medical Advisor
10. Noted Atherosclerosis Researcher Joins AtheroNova Team
11. AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 21, 2014 The ... the inorganic refrigerants market in Americas with analysis ... TOC of the Americas Inorganic Refrigerants Market report, ... provided. This also provides a glimpse of the ... is supported by various tables and figures. ...
(Date:10/22/2014)... NJ (PRWEB) October 22, 2014 ... and services – has been working with a team ... and New Haven Farms Community Farming Collaborative to provide ... ePRO solution. The study, which started in May, ... program that provides participants weekly exposure to and participation ...
(Date:10/22/2014)... October 22, 2014 According to ... by Service Type (Consulting, Integration, Deployment & Support), ... Deployment Model (Public, Private, Others (Hybrid & Community)) ... defines and segments the Cloud Professional Services Market ... forecasting of revenues. It also identifies the drivers ...
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... "Organic Electronics Market by Material, by Application, Geography ... report to their offering. Organic electronics, ... a branch of material science which deals with small ... as organic because small molecules and polymers are carbon ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... InterMune, Inc.,(Nasdaq: ITMN ) announced today that it ... 6, 2008 at 4:00 p.m. Eastern time.,A live conference ... 4:30 p.m.,Eastern time that same day., To access ... ID# 71184785. To access the,webcast, please log on to ...
... in U.S. Phase II Study,of Nitazoxanide in Treatment-Naive ... Fla., Oct. 28 Romark Laboratories, a privately,held ... nitazoxanide at the upcoming 59th Annual Meeting of ... (AASLD), also known as The,Liver Meeting(R), and the ...
... Affitech AS, the human,therapeutic antibody company, today ... to the innovative diabody technology originally owned ... vaccine company. Also known as,bi-specific single chain ... attributes make them attractive,candidates for a variety ...
Cached Biology Technology:InterMune to Release Third Quarter 2008 Financial Results on November 6 2Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2Affitech Acquires Pharmexa's Diabody Technology 2
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
(Date:10/14/2014)... new study published in Cancer Research shows ... and colon cancers—can promote the development of skin cancers ... and survival of sun-damaged skin cells. , Previously considered ... proteins called sirtuins that help regulate genomic stability and ... SIRT6 helps repair DNA damage, which can lead to ...
(Date:10/14/2014)... how to produce enough food to feed the world ... Organization of the United Nations predicts that food production ... feed a growing global population, and plants are one ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly ... tap into our knowledge of how plants work to ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... clear how salt, a scourge to agriculture, halts the growth ... the Carnegie Institution,s Jos Dinneny and Lina Duan, found that ... that an inner layer of tissue in the branching roots ... a stress hormone, which stops root growth. The study, published ...
... In a speech later today, Minister for Universities and ... research in Industrial Biotechnology and Bioenergy. The funding, from ... create networks and collaborative research between academia and industry ... UK and new ,green collar, jobs. The funding ...
... COLUMBIA, Mo. More than one-third of Americans are ... such as Type 2 diabetes and cardiovascular problems. In ... have suggested ways to improve the health outcomes of ... at the University of Missouri suggests certain exercises that ...
Cached Biology News:Breakthrough: How salt stops plant growth 2£35 million to support research for vital industrial sector 2Women must do more to reap same positive health outcomes as men, MU research suggests 2
...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
... the family of calcium binding proteins such as ... of an alpha and beta chain whereas S100B ... protein is also expressed in the antigen presenting ... and interdigitating reticulum cells in the paracortex of ...
Biology Products: